Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.19 and traded as low as $1.10. Fate Therapeutics shares last traded at $1.13, with a volume of 843,129 shares trading hands.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Fate Therapeutics in a research note on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $4.10.
Read Our Latest Analysis on FATE
Fate Therapeutics Stock Down 3.4%
The firm has a fifty day moving average price of $1.25 and a 200 day moving average price of $1.19. The company has a market cap of $131.37 million, a P/E ratio of -0.98 and a beta of 2.18.
Fate Therapeutics (NASDAQ:FATE - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.27). The business had revenue of $1.37 million during the quarter, compared to analysts' expectations of $1.20 million. Fate Therapeutics had a negative return on equity of 55.02% and a negative net margin of 2,051.08%. On average, sell-side analysts anticipate that Fate Therapeutics, Inc. will post -1.63 earnings per share for the current year.
Hedge Funds Weigh In On Fate Therapeutics
Institutional investors have recently modified their holdings of the stock. Corient Private Wealth LLC acquired a new position in shares of Fate Therapeutics during the fourth quarter worth approximately $29,000. Bridgeway Capital Management LLC acquired a new stake in shares of Fate Therapeutics in the second quarter valued at approximately $28,000. Commonwealth Equity Services LLC acquired a new stake in shares of Fate Therapeutics in the fourth quarter valued at approximately $26,000. Monaco Asset Management SAM raised its position in Fate Therapeutics by 7.8% in the 4th quarter. Monaco Asset Management SAM now owns 830,000 shares of the biopharmaceutical company's stock worth $816,000 after purchasing an additional 60,000 shares during the last quarter. Finally, Privium Fund Management B.V. raised its position in Fate Therapeutics by 10.8% in the 4th quarter. Privium Fund Management B.V. now owns 369,100 shares of the biopharmaceutical company's stock worth $363,000 after purchasing an additional 35,881 shares during the last quarter. 97.54% of the stock is owned by institutional investors.
Fate Therapeutics Company Profile
(
Get Free Report)
Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate's research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.
Central to Fate's pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fate Therapeutics wasn't on the list.
While Fate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
